AstraZeneca PLC's aim of securing the market-leading position of its biggest seller Tagrisso has received a major boost with the release of late-stage data demonstrating the additional benefit of combining the drug with chemotherapy for lung cancer patients.
The UK major has announced positive high-level results from the FLAURA2 Phase III trial which showed that Tagrisso (osimertinib) in...